| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-06-30 |
|---|---|---|---|---|
| Fair value of subscription agreement liability | - | - | - | 248,000 |
| Investment income, investment expense | - | - | - | 205,146 |
| Interest expense, debt | - | - | - | 156,169 |
| Other income | - | - | - | -31,602 |
| Total other expense | -6,714,460 | -437,024 | 4,024,944 | -640,917 |
| Loss before income taxes | -8,783,702 | -2,372,442 | -8,545,885 | -14,255,936 |
| Income tax benefit | 0 | 0 | - | 50,768 |
| Net loss | -8,783,702 | -2,372,442 | -8,545,885 | -14,306,704 |
| Other comprehensive income (loss), foreign currency translation adjustment, tax | - | - | - | -110,000 |
| Change in pension benefit obligation | - | - | - | -33,406 |
| Deemed dividend series c preferred stock | 0 | 328,504 | 1,170,091 | - |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -14,230,110 |
| Net loss applicable to common stockholders | -8,783,702 | -2,700,946 | -9,715,976 | - |
| Net loss per share, basic (in dollars per share) | -6.25 | -4.76 | -0.53 | -0.64 |
| Net loss per share, diluted (in dollars per share) | -6.25 | -4.76 | -0.53 | -0.64 |
| Weighted average number of common shares outstanding, basic (in shares) | 1,405,469 | 567,648 | 18,176,261 | 22,196,265 |
| Weighted average number of common shares outstanding, diluted (in shares) | 1,405,469 | 567,648 | 18,176,261 | 22,196,265 |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)